Gelonghui, April 17 | Xuantai Pharmaceutical rose more than 15%, while stocks such as Yuanbio, Chengdu Pioneer, Wisdom Pharmaceuticals, Haite Biotech, and Baihua Pharmaceuticals rose more than 5%. According to the news, Xuantai Pharmaceutical predicts a 201% year-on-year increase in net profit for the first quarter. In addition, Frost & Sullivan predicts that the global CRO market is expected to be about 96 billion US dollars in 2024, of which the segmented clinical CRO market accounts for the largest share, accounting for about 64% in 2022, the market size is about 51.4 billion US dollars, and is expected to grow to 62.2 billion US dollars in 2024. Furthermore, China's CRO market is growing faster than the global market.